One-stop CAR-NKT Therapy Development

Posted by Catalina Garcia on March 5th, 2024

The remarkable results of chimeric antigen receptors (CARs) clinical studies have improved the function and therapeutic efficacy of redirected T cells. However, several challenges have been encountered, and limit their anti-tumor potential and increase the risk of toxicity due to the high heterogeneity of CAR-T cells. Natural killer T cells (NKT) are immune cells, known for their powerful anti-cancer properties, and show potential for enabling autologous and allogeneic/off-the-shelf cancer immunotherapy.

At Creative Biolabs, we provide one-stop services for CAR-NKT therapy development, ranging from CAR construct design and optimization, CAR virus particle packaging, CAR carrying NKT cell engineering, to preclinical and clinical evaluation of CAR cells. We are dedicated to providing high-quality customized service to best meet your research needs, turnaround time, and budget requirements.